logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Peroxisome Proliferator Receptor alpha Agonist class drugs

    FiltersReset Filters
    5 results

    • antara

      (FENOFIBRATE)
      Lupin Pharmaceuticals, Inc.
      Usage: Antara is indicated as adjunctive therapy to diet for reducing triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL) and lowering LDL cholesterol in adults with primary hyperlipidemia when standard therapies are not possible. Its effect on pancreatitis risk and coronary heart disease outcomes is not established.

    • fenofibrate

      (fenofibrate)
      Chartwell RX, LLC.
      Usage: Fenofibrate capsules are indicated as adjunctive therapy to diet for reducing LDL-C, total cholesterol, triglycerides, and apo B in adults with primary hypercholesterolemia or mixed dyslipidemia (Types IIa and IIb), and for treating hypertriglyceridemia in adults (Types IV and V).

    • fenofibrate

      (fenofibrate)
      Mylan Pharmaceuticals Inc.
      Usage: Fenofibrate tablets are indicated as adjunctive therapy to diet for adults with primary hypercholesterolemia or mixed dyslipidemia, aiming to improve cholesterol levels. They are also used for treating severe hypertriglyceridemia, although their effect on reducing coronary heart disease risks in type 2 diabetes patients remains unproven.

    • fenofibrate

      (fenofibrate)
      Solco Healthcare US, LLC
      Usage: Fenofibrate tablets are indicated as adjunctive therapy to diet for adults with primary hypercholesterolemia, mixed dyslipidemia, or severe hypertriglyceridemia. They help reduce LDL-C, total cholesterol, triglycerides, and Apo B, while increasing HDL-C. They do not reduce coronary heart disease morbidity or mortality in diabetes patients.

    • pioglitazone and glimepiride

      (pioglitazone and glimepiride)
      Prasco Laboratories
      Usage: Pioglitazone and glimepiride tablets are indicated to improve glycemic control in adults with type 2 diabetes who are inadequately managed with a thiazolidinedione alone or sulfonylurea alone, combined with diet and exercise. Not for type 1 diabetes or diabetic ketoacidosis. Caution advised in liver disease.